Department of Biological Sciences, Simon Fraser University, 8888 University Dr, Burnaby, BC, Canada V5A 1S6.
Mol Genet Metab. 2012 Nov;107(3):571-9. doi: 10.1016/j.ymgme.2012.08.010. Epub 2012 Aug 18.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid β (Aβ) peptides and the failure of mechanisms to clear toxic aggregates. The Aβ42 peptide is considered to be a causative factor that underlies the pathophysiology of AD, in part due to its propensity for misfolding and aggregation; the small oligomers that result represent toxic species. Thus agents that prevent Aβ42 misfolding/aggregation or, alternatively improve Aβ42 oligomer clearance, may have significant therapeutic value. We have developed the basis for a drug screening system based on transgenic plant cells that express Aβ42 fusion proteins to serve as the reliable indicators of the general conformational status of Aβ42. Within cells of transgenic tobacco and Nicotiana benthamiana, misfolding of Aβ42 causes the misfolding of a GFP fusion partner, and consequently there is a loss of fluorescence associated with the native GFP protein. In a similar fusion consisting of Aβ42 linked to hygromycin phosphotransferase II (Hpt II), a hygromycin-resistance marker, misfolding of Aβ42 leads to a misfolded Hpt II, and consequently the transgenic cells are unable to grow on media containing hygromycin. Importantly, substitution of the 'aggregation-prone' Aβ42 with a missense mutant of Aβ42 (F19S/L34F) that is not prone to misfolding/aggregation, 'rescues' both fusion partners. Several 'positive control' chemicals that represent inhibitors of Aβ42 aggregation, including curcumin, epigallocatechin-3-gallate (EGCG), and resveratrol show efficacy in preventing the Aβ42-fusion proteins from misfolding/aggregating in the transgenic plant cells. We discuss the potential of the two fusion protein systems to serve as the basis for an inexpensive, selective, and efficient screening system in which a plant cell can fluoresce or survive only in the presence of drug candidates that are able to prevent Aβ42 misfolding/aggregation.
阿尔茨海默病(AD)是一种进行性神经退行性疾病,其特征是淀粉样β(Aβ)肽的积累和清除有毒聚集体的机制失效。Aβ42 肽被认为是 AD 病理生理学的基础致病因素,部分原因是其易于错误折叠和聚集;由此产生的小寡聚体是有毒物质。因此,能够防止 Aβ42 错误折叠/聚集的药物,或者能够改善 Aβ42 寡聚体清除的药物,可能具有重要的治疗价值。我们已经开发了一种基于表达 Aβ42 融合蛋白的转基因植物细胞的药物筛选系统的基础,该系统可作为 Aβ42 一般构象状态的可靠指标。在转基因烟草和黄花烟的细胞内,Aβ42 的错误折叠导致 GFP 融合伴侣的错误折叠,从而导致与天然 GFP 蛋白相关的荧光丧失。在由 Aβ42 与潮霉素磷酸转移酶 II(Hpt II)连接的类似融合物中,Aβ42 的错误折叠导致错误折叠的 Hpt II,因此转基因细胞无法在含有潮霉素的培养基上生长。重要的是,用不易错误折叠/聚集的 Aβ42 错义突变体(F19S/L34F)代替“易于聚集的”Aβ42,可“挽救”两种融合伴侣。几种“阳性对照”化学物质,包括姜黄素、表没食子儿茶素-3-没食子酸酯(EGCG)和白藜芦醇,在防止 Aβ42 融合蛋白在转基因植物细胞中错误折叠/聚集方面表现出功效。我们讨论了这两种融合蛋白系统作为廉价、选择性和高效筛选系统的基础的潜力,在该系统中,只有能够防止 Aβ42 错误折叠/聚集的药物候选物存在时,植物细胞才能发光或存活。